Diabetes Care：GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗

2014-06-19 MedSci MedSci原创

HNF1A糖尿病[青少年的成年发病型糖尿病(MODY)3型]患者通常使用磺脲类药物治疗，面临低血糖频发风险。第2项研究是一项双盲、随机、交叉试验，探索GLP-1受体激动剂能否作为有效的替代选择。研究纳入的16例HNF1A糖尿病患者随机接受格列美脲(n=8)或利拉鲁肽 (n=8)治疗6周。结果表明，两组患者的空腹血糖(FPG，主要疗效终点)和餐后血糖水平均较基线显著下降，胰岛素和C肽反应提

HNF1A糖尿病[青少年的成年发病型糖尿病(MODY)3型]患者通常使用磺脲类药物治疗，面临低血糖频发风险。第2项研究是一项双盲、随机、交叉试验，探索GLP-1受体激动剂能否作为有效的替代选择。研究纳入的16例HNF1A糖尿病患者随机接受格列美脲(n=8)或利拉鲁肽 (n=8)治疗6周。

结果表明，两组患者的空腹血糖(FPG，主要疗效终点)和餐后血糖水平均较基线显著下降，胰岛素和C肽反应提高，组间均无显著性差异;利拉鲁肽组低血糖事件显著更少(18次对1次)。作者就此指出GLP-1受体激动剂有望在MODY患者、特别是治疗相关低血糖事件频发患者的治疗中占有一席。

原始出处：

Ostoft SH, Bagger JI, Hansen T, Pedersen O, Faber J, Holst JJ, Knop FK, Vilsbøll T.Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial.Diabetes Care. 2014 Jun 14. pii: DC_133007

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (9)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2015-04-11 x35042875

国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

141 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2014-08-28 wfang555

#替代治疗#

69 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2015-02-22 木头人513

#Diabetes#

58 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2014-11-21 智智灵药

#BET#

48 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2015-04-05 ms9608593228839890

#DIA#

58 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2015-04-07 fusion

#MODY#

66 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2014-06-21 Eleven11

#GLP-1受体激动剂#

74 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2014-06-21 yibei

#GLP-1#

54 0
[GetPortalCommentsPageByObjectIdResponse(id=20755, encodeId=006d20e5505, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:41:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692824, encodeId=2b151692824fd, content=<a href='/topic/show?id=e6d86032ee8' target=_blank style='color:#2F92EE;'>#替代治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60327, encryptionId=e6d86032ee8, topicName=替代治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79d29305168, createdName=wfang555, createdTime=Thu Aug 28 10:57:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901224, encodeId=5c7c19012243b, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 22 05:57:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759465, encodeId=10431e59465b3, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 21 02:57:00 CST 2014, time=2014-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636895, encodeId=2b111636895d4, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Apr 05 00:57:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720616, encodeId=68cb1e20616f2, content=<a href='/topic/show?id=08ca120e6bd' target=_blank style='color:#2F92EE;'>#MODY#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12076, encryptionId=08ca120e6bd, topicName=MODY)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed7332890368, createdName=fusion, createdTime=Tue Apr 07 14:57:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294020, encodeId=bf17129402072, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422687, encodeId=14e1142268e5f, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627723, encodeId=a018162e72310, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Sat Jun 21 12:57:00 CST 2014, time=2014-06-21, status=1, ipAttribution=)]
2014-06-21 medscijoin

#激动剂#

55 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

Diabetes Care：GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗

相关资讯

科室

工具

服务